Sanctuary Advisors LLC Buys New Shares in Stryker Corporation $SYK

Sanctuary Advisors LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 68,875 shares of the medical technology company’s stock, valued at approximately $21,685,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter valued at about $27,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth about $26,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the fourth quarter worth approximately $27,000. Finally, Gables Capital Management Inc. bought a new stake in Stryker in the second quarter valued at approximately $25,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of NYSE SYK opened at $329.86 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s fifty day moving average price is $326.99 and its two-hundred day moving average price is $332.39. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The firm has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 665,370 shares of company stock valued at $216,238,501 in the last quarter. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SYK. Truist Financial raised their price objective on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research report on Friday, May 1st. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Citigroup reissued a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.